Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Zelboraf
(United States) [Available]Synonyms :
Vemurafenib
Class :
Antineoplastics and BRAF Kinase Inhibitor
Brand Name :
Zelboraf
(United States) [Available]Synonyms :
Vemurafenib
Class :
Antineoplastics and BRAF Kinase Inhibitor
960
mg
Tablet
Orally
every 12 hrs
Continue the therapy until disease progression or unacceptable toxicity occurs
960
mg
Tablet
Orally
every 12 hrs
Continue the therapy until disease progression or unacceptable toxicity occurs
Safety and efficacy are not studied
Safety and efficacy are not studied
Refer adult dosing
Refer adult dosing
Refer adult dosing
CYP1A2 Inhibitors may increase the serum concentration of Alosetron
aminolevulinic Acid (Systemic)
when both drusa aed Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic)
vemurafenib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
vemurafenib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
vemurafenib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
vemurafenib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
vemurafenib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
may increase the QTc prolonging effect of QT-prolonging agents
QTc interval is increased both by lenvatinib and vemurafenib
may increase the QT-prolonging effect and enhance the risk of bradycardia, hypokalemia
when used together, azithromycin and vemurafenib both increase the QTc interval
CYP3A strong enhancers of the small intestine may reduce the bioavailability of vemurafenib
vemurafenib and gilteritinib, when used in combination, increase the QTc interval
P-glycoprotein or ABCB1 Inhibitors may increase the serum concentration of Aliskiren
vemurafenib: they may diminish the serum concentration of CYP3A4 Inducers
vemurafenib: they may diminish the serum concentration of CYP3A4 Inducers
vemurafenib: they may diminish the serum concentration of CYP3A4 Inducers
vemurafenib: they may diminish the serum concentration of CYP3A4 Inducers
vemurafenib: they may diminish the serum concentration of CYP3A4 Inducers
It may enhance the effect when combined with tafamidis meglumine
vemurafenib: they may enhance the serum concentration of CYP3A4 Inhibitors
vemurafenib: they may enhance the serum concentration of CYP3A4 Inhibitors
vemurafenib: they may enhance the serum concentration of CYP3A4 Inhibitors
vemurafenib: they may enhance the serum concentration of CYP3A4 Inhibitors
vemurafenib: they may enhance the serum concentration of CYP3A4 Inhibitors
when both drugs are combined, there may be a high metabolism of vemurafenib
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
the effect of vemurafenib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
may increase serum levels of docetaxel
when both drugs are combined, there may be an increased risk of infection
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
may increase the QTc prolonging effect
An oral inhibitor of mutant BRAF-serine-threonine kinase is called vemurafenib.
The mutant forms of BRAF are competitively inhibited by this drug.
It is particularly effective against the mutation BRAF V600E
Vemurafenib inhibits the growth of tumors by blocking downstream pathways, which causes apoptosis.
Melanoma cell lines with the wild-type BRAF mutation are not susceptible to the antitumor effects of vemurafenib.
Adverse drug reactions:
Frequency defined
>10%
>10%:
neuropathy
headache
skin rash
skin photosensitivity
xeroderma
palmar-plantar erythrodysesthesia
pruritus
nevussunburn
papular rash
erythema
None
Contraindication:
None
Caution:
Anaphylaxis and other serious hypersensitivity reactions
Dermatologic reactions
Liver injury
Ophthalmologic reactions
Pregnancy warnings:
Breastfeeding warnings:
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first trimester or the later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
An intermediate molecule in MAPK, BRAF is activated by ERK activation, cyclin D1 increase, and cellular proliferation.
Vemurafenib has reported to decrease all BRAF-related activation indicators.
Every research suggests that Vemurafenib produces a nearly total blockage of the MAPK pathway.
Cytoplasmic phosphorylated ERK was reduced after vemurafenib treatment, and Ki-67-driven cell growth was observed.
It is taken orally in tablet form with or without food.
Swallow whole at time with glass of water and do not try to chew or crush.
Take in the morning and the evening, about 12 hours intervals.
Do not take both doses at the same time; if a dose is missed, it can be taken up to 4 hours before the next dose to keep the twice-daily schedule.
If vomiting occurs after administration, take the following dose as planned instead of taking another one.
Patient information leaflet
Generic Name: vemurafenib
Why do we use vemurafenib?
Vemurafenib is indicated for the treatment of metastatic melanoma with a mutation on BRAF.
The central nervous system, major bones, and large vasculature are all impacted by the highly rare histiocyte cell condition known as Erdheim-Chester disease.
It is used to treat Erdheim-Chester disease with V600E mutation.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
